Director/PDMR Shareholding

Paris, France and Camberley, UK – 06 July 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 05 July 2021, Guillermo Raimondo, Chief Commercial Officer of the Company, acquired 10,000 ordinary shares of €1/15 each in the Company at a price of €3.85 per share.  The resultant beneficial shareholding of Mr Raimondo is 10,000 ordinary shares representing 0.01% of the Company’s issued share capital.

http://novacyt.com/wp-content/uploads/2021/07/Novacyt-Directors-Dealings-RNS-Guillermo-Raimondo-ENGLISH-06.07.2021.pdf